Non-mavacamten symptomatic oHCM therapy
PreclinicalSmall molecule
Bristol-Myers SquibbNon-mavacamten symptomatic oHCM therapy is one of 38 small molecule programs targeting Hypertrophic Cardiomyopathy. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Hypertrophic Cardiomyopathy
#DrugCompanyPhaseTrials
1Aldactone
PfizerApproved
Adenocard
AstellasApproved
Lexiscan
AstellasApproved
Zebeta
TevaApproved
Bayer Aspirin
BayerApproved
Cardizem
BBausch Health Americas, Inc.
Approved
Camzyos
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Calan
VVal Adams
Approved
Xarelto
WWim Janssens
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company